ECSP055679A - Derivados de pirazol como inhibidores del factor del crecimiento transformante (tgf) - Google Patents

Derivados de pirazol como inhibidores del factor del crecimiento transformante (tgf)

Info

Publication number
ECSP055679A
ECSP055679A EC2005005679A ECSP055679A ECSP055679A EC SP055679 A ECSP055679 A EC SP055679A EC 2005005679 A EC2005005679 A EC 2005005679A EC SP055679 A ECSP055679 A EC SP055679A EC SP055679 A ECSP055679 A EC SP055679A
Authority
EC
Ecuador
Prior art keywords
tgf
derivatives
growth factor
transforming growth
inhibitors
Prior art date
Application number
EC2005005679A
Other languages
English (en)
Inventor
Laura Cook Blumberg
Michael John Munchhof
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP055679A publication Critical patent/ECSP055679A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen nuevos compuestos de pirazol, incluyendo sus derivados, intermedios para su preparación, composiciones farmacéuticas que los contienen y su uso medicinal. Los compuestos de la presente invención son inhibidores potentes de la ruta de señalización del factor de crecimiento transformante (TGF)-B. Son de utilidad en el tratamiento de diversos estados de enfermedad relacionados con TGF incluyendo, por ejemplo cáncer y enfermedades fibróticas.
EC2005005679A 2002-09-18 2005-03-16 Derivados de pirazol como inhibidores del factor del crecimiento transformante (tgf) ECSP055679A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41214602P 2002-09-18 2002-09-18
US48454303P 2003-07-02 2003-07-02

Publications (1)

Publication Number Publication Date
ECSP055679A true ECSP055679A (es) 2005-05-30

Family

ID=32033585

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005679A ECSP055679A (es) 2002-09-18 2005-03-16 Derivados de pirazol como inhibidores del factor del crecimiento transformante (tgf)

Country Status (27)

Country Link
US (4) US6958354B2 (es)
EP (2) EP2165708A3 (es)
JP (1) JP4519657B2 (es)
KR (1) KR20050044807A (es)
CN (1) CN1681501A (es)
AP (1) AP2005003263A0 (es)
AR (1) AR041272A1 (es)
AT (1) ATE450258T1 (es)
AU (1) AU2003259475A1 (es)
BR (1) BR0314302A (es)
CA (1) CA2496295C (es)
CO (1) CO5550456A2 (es)
DE (1) DE60330362D1 (es)
EA (1) EA200500377A1 (es)
EC (1) ECSP055679A (es)
ES (1) ES2335099T3 (es)
HR (1) HRP20050247A2 (es)
IS (1) IS7698A (es)
MA (1) MA27440A1 (es)
MX (1) MXPA05002376A (es)
NO (1) NO20050838L (es)
OA (1) OA12929A (es)
PA (1) PA8583201A1 (es)
PE (1) PE20040988A1 (es)
PL (1) PL375979A1 (es)
UY (1) UY27985A1 (es)
WO (1) WO2004026306A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA12929A (en) * 2002-09-18 2006-10-13 Pfizer Prod Inc Pyrazole derivatives as transforming growth (TGF) inhibitors.
KR20050057392A (ko) * 2002-09-18 2005-06-16 화이자 프로덕츠 인크. 전환성장인자(ｔｇｆ) 억제제로서의 신규한 이미다졸 화합물
MXPA05002332A (es) 2002-09-18 2005-06-08 Pfizer Prod Inc Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf).
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
GB0313915D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
US20080171755A1 (en) * 2004-08-31 2008-07-17 Wen-Cherng Lee Pyrimidinylpyrazoles as Tgf-Beta Inhibitors
US20070275968A1 (en) * 2004-09-07 2007-11-29 Hitoshi Kurata Substituted Biphenyl Derivative
AU2005295734A1 (en) * 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
WO2007070866A2 (en) * 2005-12-16 2007-06-21 Alcon, Inc. Control of intraocular pressure using alk5 modulation agents
AP2527A (en) 2006-10-31 2012-12-06 Pfizer Prod Inc Pyrazoline compounds as mineralocorticoid receptorantagonists
KR20100038119A (ko) * 2007-08-01 2010-04-12 화이자 인코포레이티드 피라졸 화합물 및 ｒａｆ 억제제로서 이의 용도
CN109045032A (zh) 2014-01-01 2018-12-21 麦迪威森技术有限责任公司 氨基吡啶类化合物和使用方法
WO2016160881A1 (en) 2015-04-01 2016-10-06 Rigel Pharmaceuticals, Inc. TGF-β INHIBITORS
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
WO2017215506A1 (zh) * 2016-06-13 2017-12-21 南京明德新药研发股份有限公司 作为TGF-βR1抑制剂的苯并三氮唑衍生的α，β不饱和酰胺类化合物
WO2018081401A1 (en) * 2016-10-26 2018-05-03 Ichan School Of Medicine At Mount Sinai Method for increasing cell proliferation in pancreatic beta cells, treatmen t method.and composition
CN108779100B (zh) * 2016-11-14 2021-11-16 江苏恒瑞医药股份有限公司 3,4-二吡啶基吡唑类衍生物、其制备方法及其在医药上的应用
WO2019100062A1 (en) 2017-11-20 2019-05-23 Ichan School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
PT3725786T (pt) * 2017-12-13 2023-10-17 Genfleet Therapeutics Shanghai Inc Forma cristalina e forma salina de inibidor de tgf-bri e método de preparação das mesmas
CN111819193A (zh) 2018-01-05 2020-10-23 西奈山伊坎医学院 增加胰腺β细胞增殖的方法、治疗方法以及组合物
AU2019240065A1 (en) 2018-03-20 2020-09-24 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
TW202012390A (zh) * 2018-06-29 2020-04-01 日商日本歐愛特農業科技股份有限公司 新穎之經取代吡唑衍生物
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
AU2019396360A1 (en) 2018-12-11 2021-05-27 Theravance Biopharma R&D Ip, Llc Naphthyridine and quinoline derivatives useful as ALK5 inhibitors
CN110467601B (zh) * 2019-08-29 2021-07-02 杭州市西溪医院 一种吡唑联吡啶酮类化合物、中间体及其制备方法及应用
IL293084A (en) 2019-11-22 2022-07-01 Theravance Biopharma R& D Ip Llc Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors
PH12022551177A1 (en) 2019-11-28 2024-02-05 Agomab Spain S L U Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
EP3978487A1 (en) 2020-09-30 2022-04-06 Origo Biopharma, S.L. 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (es) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4925857A (en) * 1989-03-22 1990-05-15 Sterling Drug Inc. Pyridinyl-1H-pyrazole-1-alkanamides as antiarrhythmic agents
JP3734180B2 (ja) * 1994-12-28 2006-01-11 エーザイ株式会社 新規ピラゾール誘導体
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
AR037061A1 (es) 1997-05-22 2004-10-20 Searle & Co Compuesto derivado de pirazol sustituido, procesos para preparar dicho compuesto, composicion farmaceutica que lo contiene y su uso en la preparacion de medicamentos
JP2002502380A (ja) 1997-05-22 2002-01-22 ジー．ディー．サール アンド カンパニー ｐ３８キナーゼ阻害剤としてのピラゾール誘導体
JP2002541253A (ja) 1999-04-09 2002-12-03 スミスクライン・ビーチャム・コーポレイション トリアリールイミダゾール
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US20040039198A1 (en) 2000-11-16 2004-02-26 Bender Paul E. Compounds
GB0027987D0 (en) 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
GB0100762D0 (en) 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
JP2004521901A (ja) * 2001-02-02 2004-07-22 グラクソ　グループ　リミテッド Ｔｇｆ阻害剤としてのピラゾール
US20040087623A1 (en) * 2001-02-02 2004-05-06 Gellibert Francoise Jeanne Pyrazole derivatives against tgf overexpression
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
EP1370557B1 (en) 2001-03-09 2005-11-16 Pfizer Products Inc. Benzimidazole anti-inflammatory compounds
JP4310109B2 (ja) 2001-04-26 2009-08-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾリル基を置換基として有する含窒素縮合環化合物およびその医薬組成物
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
AU2003260345A1 (en) 2002-07-31 2004-02-23 Smithkline Beecham Corporation 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
OA12927A (en) 2002-09-18 2006-10-13 Pfizer Prod Inc Novel triazole and oxazole compounds as transforming growth factor (TGF) inhibitors.
OA12925A (en) 2002-09-18 2006-10-13 Pfizer Prod Inc Novel isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors.
MXPA05002332A (es) 2002-09-18 2005-06-08 Pfizer Prod Inc Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf).
KR20050057392A (ko) 2002-09-18 2005-06-16 화이자 프로덕츠 인크. 전환성장인자(ｔｇｆ) 억제제로서의 신규한 이미다졸 화합물
OA12929A (en) * 2002-09-18 2006-10-13 Pfizer Prod Inc Pyrazole derivatives as transforming growth (TGF) inhibitors.
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)

Also Published As

Publication number Publication date
AR041272A1 (es) 2005-05-11
UY27985A1 (es) 2004-04-30
EA200500377A1 (ru) 2005-08-25
ATE450258T1 (de) 2009-12-15
CN1681501A (zh) 2005-10-12
US7638537B2 (en) 2009-12-29
WO2004026306A3 (en) 2004-07-01
HRP20050247A2 (en) 2005-10-31
ES2335099T3 (es) 2010-03-22
BR0314302A (pt) 2005-07-05
KR20050044807A (ko) 2005-05-12
JP2006507353A (ja) 2006-03-02
US20100056571A1 (en) 2010-03-04
AU2003259475A1 (en) 2004-04-08
OA12929A (en) 2006-10-13
PE20040988A1 (es) 2004-12-25
US20070117850A1 (en) 2007-05-24
EP1542684B1 (en) 2009-12-02
CA2496295C (en) 2010-11-23
CO5550456A2 (es) 2005-08-31
CA2496295A1 (en) 2004-04-01
AP2005003263A0 (en) 2005-03-31
EP1542684A2 (en) 2005-06-22
JP4519657B2 (ja) 2010-08-04
DE60330362D1 (de) 2010-01-14
US6958354B2 (en) 2005-10-25
MA27440A1 (fr) 2005-07-01
US20060025451A1 (en) 2006-02-02
US7151110B2 (en) 2006-12-19
US20040116474A1 (en) 2004-06-17
IS7698A (is) 2005-02-17
EP2165708A3 (en) 2010-07-28
MXPA05002376A (es) 2005-05-23
WO2004026306A2 (en) 2004-04-01
PA8583201A1 (es) 2004-04-23
PL375979A1 (en) 2005-12-12
NO20050838L (no) 2005-05-18
EP2165708A2 (en) 2010-03-24

Similar Documents

Publication Publication Date Title
UY27982A1 (es) Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf)
UY27981A1 (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
UY27985A1 (es) Nuevos compuestos de imidazol domo inhibidores del factor de crecimiento transformante (tgf)
UY28214A1 (es) Nuevos compuestos heteroaromáticos condensados que son inhibidores del factor de crecimiento transformante (tgf)
PA8582701A1 (es) Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
UY27983A1 (es) Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf)
PA8592301A1 (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
BRPI0408251A (pt) compostos de pirazina como inibidores do fator de crescimento transformante (tgf)
UY27891A1 (es) Nuevos derivados de glicosido de tiofeno, procedimientos para la preparación de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos.
AR048912A1 (es) Inmunoglobulinas anti-nogo
UY28679A1 (es) Nuevos derivados organofosforados de los indazoles y utilización como médicamentos.
UY28572A1 (es) Compuestos novedosos
ECSP055967A (es) N-arilheterociclos sustituidos, procedimientos para su preparación, y su empleo como medicamentos
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
AR057222A1 (es) Agonistas del receptor del neuropeprtido -2
CR7195A (es) Nuevos derivados de oxazolidinonas como antibacterianos
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.
CR7748A (es) Nuevos compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf)
DOP2003000718A (es) Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf)
CR7749A (es) Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf)
DOP2003000713A (es) Nuevos compuestos de pirarol como inhibidores delfactor de crecimiento transformante (tgf)
DOP2003000712A (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
DOP2003000701A (es) Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
DOP2003000719A (es) Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf)
CR7747A (es) Nuevos compuestos derivados de isoxazol como inhibidores del factor de crecimiento transformador (tgf)